These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1587075)

  • 1. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase.
    Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Cox C; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):608-14. PubMed ID: 1587075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.
    Weintraub M; Sundaresan PR; Madan M; Schuster B; Balder A; Lasagna L; Cox C
    Clin Pharmacol Ther; 1992 May; 51(5):586-94. PubMed ID: 1587072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication.
    Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):615-8. PubMed ID: 1587076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise.
    Weintraub M; Sundaresan PR; Schuster B; Ginsberg G; Madan M; Balder A; Stein EC; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):595-601. PubMed ID: 1587073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
    Weintraub M; Hasday JD; Mushlin AI; Lockwood DH
    Arch Intern Med; 1984 Jun; 144(6):1143-8. PubMed ID: 6375610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term weight control study. VI. Individual participant response patterns.
    Weintraub M; Sundaresan PR; Cox C
    Clin Pharmacol Ther; 1992 May; 51(5):619-33. PubMed ID: 1587077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine.
    Weintraub M; Sundaresan PR; Schuster B; Moscucci M; Stein EC
    Clin Pharmacol Ther; 1992 May; 51(5):602-7. PubMed ID: 1587074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic induction of weight loss to treat type 2 diabetes.
    Redmon JB; Raatz SK; Kwong CA; Swanson JE; Thomas W; Bantle JP
    Diabetes Care; 1999 Jun; 22(6):896-903. PubMed ID: 10372238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
    Hensrud DD; Connolly HM; Grogan M; Miller FA; Bailey KR; Jensen MD
    Mayo Clin Proc; 1999 Dec; 74(12):1191-7. PubMed ID: 10593346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term drug treatment of obesity in a private practice setting.
    Atkinson RL; Blank RC; Schumacher D; Dhurandhar NV; Ritch DL
    Obes Res; 1997 Nov; 5(6):578-86. PubMed ID: 9449143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release fenfluramine: patient acceptance and efficacy of evening dosing.
    Weintraub M; Sriwatanakul K; Sundaresan PR; Weis OF; Dorn M
    Clin Pharmacol Ther; 1983 May; 33(5):621-7. PubMed ID: 6340909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term weight control study. VII (weeks 0 to 210). Serum lipid changes.
    Weintraub M; Sundaresan PR; Schuster B
    Clin Pharmacol Ther; 1992 May; 51(5):634-41. PubMed ID: 1587078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
    Tronieri JS; Wadden TA; Walsh OA; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Chao AM
    Metabolism; 2019 Jul; 96():83-91. PubMed ID: 30902750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term weight control study: conclusions.
    Weintraub M
    Clin Pharmacol Ther; 1992 May; 51(5):642-6. PubMed ID: 1587079
    [No Abstract]   [Full Text] [Related]  

  • 15. The fen-phen finale: a study of weight loss and valvular heart disease.
    Wadden TA; Berkowitz RI; Silvestry F; Vogt RA; St John Sutton MG; Stunkard AJ; Foster GD; Aber JL
    Obes Res; 1998 Jul; 6(4):278-84. PubMed ID: 9688104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study.
    Weintraub M
    Clin Pharmacol Ther; 1992 May; 51(5):581-5. PubMed ID: 1445528
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of a combined behavioral and pharmacological program on weight loss.
    Brightwell DR; Naylor CS
    Int J Obes; 1979; 3(2):141-8. PubMed ID: 528125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of phentermine and fenfluramine on alcohol consumption and alcohol withdrawal seizures in rats.
    Halladay AK; Fisher H; Wagner GC
    Alcohol; 2000 Jan; 20(1):19-29. PubMed ID: 10680713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful appetite suppression therapy with fenfluramine and phentermine in the obese diabetic transplant patient.
    Khan M; Lum CT; Rao V
    Transplant Proc; 1995 Feb; 27(1):975-6. PubMed ID: 7879251
    [No Abstract]   [Full Text] [Related]  

  • 20. Platelet alpha-adrenergic receptors in obesity: alteration with weight loss.
    Sundaresan PR; Weintraub M; Hershey LA; Kroening BH; Hasday JD; Banerjee SP
    Clin Pharmacol Ther; 1983 Jun; 33(6):776-85. PubMed ID: 6303674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.